BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

867 related articles for article (PubMed ID: 31134427)

  • 1. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
    Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
    Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity.
    Ohtani K; Ide T; Hiasa KI; Sakamoto I; Yamashita N; Kubo M; Tsutsui H
    Clin Res Cardiol; 2019 Oct; 108(10):1128-1139. PubMed ID: 30859381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis.
    Kalam K; Marwick TH
    Eur J Cancer; 2013 Sep; 49(13):2900-9. PubMed ID: 23706982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab.
    Gujral DM; Lloyd G; Bhattacharyya S
    Breast; 2018 Feb; 37():64-71. PubMed ID: 29101824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common Cardiovascular Complications of Cancer Therapy: Epidemiology, Risk Prediction, and Prevention.
    Narayan V; Ky B
    Annu Rev Med; 2018 Jan; 69():97-111. PubMed ID: 29414258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity.
    Blanter JB; Frishman WH
    Cardiol Rev; 2019; 27(5):256-259. PubMed ID: 31008768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
    Guglin M; Munster P; Fink A; Krischer J
    Am Heart J; 2017 Jun; 188():87-92. PubMed ID: 28577685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.
    Hussain Y; Drill E; Dang CT; Liu JE; Steingart RM; Yu AF
    Breast Cancer Res Treat; 2019 May; 175(1):239-246. PubMed ID: 30721443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure.
    Armenian SH; Hudson MM; Chen MH; Colan SD; Lindenfeld L; Mills G; Siyahian A; Gelehrter S; Dang H; Hein W; Green DM; Robison LL; Wong FL; Douglas PS; Bhatia S
    BMC Cardiovasc Disord; 2016 Oct; 16(1):187. PubMed ID: 27716152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
    Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
    J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotoxicity of Contemporary Breast Cancer Treatments.
    Lee Chuy K; Yu AF
    Curr Treat Options Oncol; 2019 May; 20(6):51. PubMed ID: 31073788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
    Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
    Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
    Yoon GJ; Telli ML; Kao DP; Matsuda KY; Carlson RW; Witteles RM
    J Am Coll Cardiol; 2010 Nov; 56(20):1644-50. PubMed ID: 21050974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart failure from cancer therapy: can we prevent it?
    Totzeck M; Mincu RI; Heusch G; Rassaf T
    ESC Heart Fail; 2019 Aug; 6(4):856-862. PubMed ID: 31297946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure.
    Seicean S; Seicean A; Alan N; Plana JC; Budd GT; Marwick TH
    Circ Heart Fail; 2013 May; 6(3):420-6. PubMed ID: 23425978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
    Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
    Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.
    Henry ML; Niu J; Zhang N; Giordano SH; Chavez-MacGregor M
    JACC Cardiovasc Imaging; 2018 Aug; 11(8):1084-1093. PubMed ID: 30092967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.
    Bergler-Klein J; Rainer PP; Wallner M; Zaruba MM; Dörler J; Böhmer A; Buchacher T; Frey M; Adlbrecht C; Bartsch R; Gyöngyösi M; Fürst UM
    Wien Klin Wochenschr; 2022 Sep; 134(17-18):654-674. PubMed ID: 35507087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.
    Drafts BC; Twomley KM; D'Agostino R; Lawrence J; Avis N; Ellis LR; Thohan V; Jordan J; Melin SA; Torti FM; Little WC; Hamilton CA; Hundley WG
    JACC Cardiovasc Imaging; 2013 Aug; 6(8):877-85. PubMed ID: 23643285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracycline-related cardiotoxicity in childhood cancer survivors.
    Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
    Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.